November 21, 2026

Mixed bag for pharma firms on DSE

While Keya Cosmetics, Square Pharma and Libra Infusion raise profits, 5 of 8 pharma companies indicate relatively lower profits in Oct-Dec quarter, Farhan Fardaus finds.

bdnews24.com News Service

bdnews24.com

Published : 16 Feb 2012, 01:35 PM

Updated : 09 Aug 2022, 03:25 PM

Farhan Fardaus bdnews24.com correspondent Dhaka, Feb 16 (bdnews24.com) – Five of eight pharmaceutical companies listed on Dhaka Stock Exchange have declared lower profit after tax for the October-December quarter. The eight companies have published their unaudited financial statement in accordance to a directive by the Securities and Exchange Commission (SEC) for the second quarter of this fiscal. Keya Cosmetics posted a 68-percent more profit after tax than what it posted for the same quarter last year, whereas Square Pharmaceuticals and Libra Infusion saw a 12 and 8-percent growth, respectively, in the same period on a year-on-year basis. Orion Infusion indicated 60 percent lower profit after tax than for same quarter last year, while Beacon, Marico, Pharmaaid and Kohinoor posted 40, 25, 16 and 6 percent, respectively, lower profit. With Tk 52.8 billion market capitalisation Square Pharma is the biggest among 20 pharmaceutical companies listed on DSE. The pharma sector's market capitalisation is around Tk 139 billion. The sector has 6.16 percent of the total market capitalisation of DSE as of February 12, 2012 market price, the premier bourse's total market capitalisation being Tk 2,253 billion. Eleven companies among 20 that peg their financial yearend in December will publish audited financial statements with dividend declaration shortly. Of the other nine, Imam Button has not published an unaudited financial statement yet, against SEC directives. Imam Button reported Tk 1.6 million losses after tax, according to an unaudited financial statement in the previous (July-August 2011) quarter, whereas during the same period last year it had indicated a Tk 5.9 million loss. The firm, with Tk 110 million market capitalization, had suffered a Tk 13 million loss in the 2010-11 fiscal, according to an audited statement. The loss for 2009-10 was Tk 9 million. Imam Button is the smallest market capitalised company in the pharmaceutical sector. FIRMS WITH YEAR ENDING DECEMBER Among 11 companies with yearend in December, Glaxo SmithKline has already declared its dividend with the audited financial statement. The company, with Tk 7 billion market capitalization, declared 150 percent cash dividend on face value, 25 percent less than that of the previous year. The fifth largest company among pharma firms listed on DSE, Glaxo had a 3-percent increase in its net asset value (NAV) per share, whereas EPS (earning per share) decreased by 31 percent. Among the other 10 companies with a December yearend, nine showed more profit after tax in the January-September 2011 period than the same period in 2010, according to unaudited financial statement. Renata Ltd, the second largest firm in the sector, saw a 16-percent growth in profit after tax for the nine-month period last year, according to unaudited financial statement, whereas the third largest, Beximco Pharma, indicated a 15.2-percent growth in their unaudited profit-after-tax figures. Reckitt, Ibn Sina, and ACI reported 10.9, 2.8, and .06 percent growth, respectively, for the same period. Prof Osman Imam of Dhaka University's finance department, who is a renowned financial analyst, said, "Products in this industry (pharmna sector) have an inelastic demand (increase in price do not decrease product's demand. However, as this is an import-dependent industry, adverse changes in exchange rate may increase the cost of production." Beximco Synthetic had around 670 percent growth in profit after tax than last year in its unaudited statement for January to September 2011, where Active Fine Chemical and ACI Formulation Limited reported 239 and 309 percent growth, respectively. A Dhaka University professor, who teaches finance, said, "Some companies are manipulating financial statements on purpose." bdnews24.com/ffs/tk/std/1650h
Related Stories